Complete response and survival outcomes in patients with advanced cancer on immune checkpoint inhibitors
Abstract
Aim: To evaluate overall survival in advanced cancer patients who achieved complete response (CR) with immune checkpoint inhibitor (ICI) therapy. Methods: This retrospective study included patients with advanced unresectable or metastatic cancer who received at least one cycle of palliative-intent ICI. Best overall response was used to define response groups. Results: 21 (7%) of 322 patients achieved CR. Multivariate analysis demonstrated that CR was independently associated with better overall survival compared with disease progression (hazard ratio: 0.012; 95% CI: 0.002–0.090) and stable disease (hazard ratio: 0.063; 95% CI: 0.009–0.464) as well as a nonsignificant trend toward better overall survival compared with partial response (hazard ratio: 0.169; 95% CI: 0.023–1.252) regardless of cancer type, ICI regimen or ICI line. Conclusion: Patients who achieved CR had longer survival compared with patients who did not achieve CR.
Papers of special note have been highlighted as: • of interest
References
- 1. US FDA. Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry (2018). www.fda.gov/downloads/drugsGuidanceComplianceRegulatoyInformation/Guidance/UCM071590.pdf
- 2. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: a meta-regression of randomised prospective studies. Eur. J. Cancer 86, 257–265 (2017).
- 3. . Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials. Clin. Cancer Res. 24, 2268–2275 (2018).
- 4. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
- 5. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
- 6. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
- 7. Pembrolizumab versus chemotherapy for PD-L1-positive-non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
- 8. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018).
- 9. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).
- 10. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 5(6), e001079 (2020).
- 11. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomized, open-label, phase 3 trial. Lancet Oncol. 21, 1563–1573 (2020).
- 12. Updated efficacy from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann. Oncol. 31, 1030–1039 (2020).
- 13. Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. N. Engl. J. Med. 384, 829–841 (2021).
- 14. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289–1300 (2021).
- 15. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009). • Of interest because the authors' study utilized Response Evaluation Criteria in Solid Tumors (RECIST) as the reference for classifying best objective response.
- 16. . Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. J. Gastrointest. Oncol. 8, 39–48 (2017).
- 17. . Survival outcomes for patients with clinical complete response after neoadjuvant chemotherapy: is omitting surgery an option? Ann. Surg. Oncol. 26, 3260–3268 (2019).
- 18. Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis. Cancer Res. 80(24), 5427–5434 (2020).
- 19. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann. Oncol. 30, 582–588 (2019).
- 20. Depth of response (DEPOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101. Oncol. Res. Treat. 43(Suppl. 1), 225 (2020). • Of interest because of potential evaluation of durable response versus maximal tumor response rather than use of conventional RECIST.
- 21. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J. Clin. Oncol. 38. 1655–1665 (2020).
- 22. A long-term survival in patients responding to anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Clin. Cancer Res. 25, 946–956 (2019).
- 23. Relevance of randomised controlled trials in oncology. Lancet Oncol. 17, e560–e567 (2016).
- 24. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow up of a randomized phase 3 clinical trial. J. Immunother. Cancer 8, e000891 (2020).
- 25. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J. Clin. Oncol. 36, 1668–1674 (2018).
- 26. ClinicalTrials.gov. Duration of anti-PD-1 therapy in metatatic melanoma (STOP-GAP) (2022). https://clinicaltrials.gov/ct2/show/NCT02821013?recrs=a&cond=melanoma&cntry=CA&city=kingston&draw=2&rank=2